Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2322213 | 1.00 | CRHR1 (1.00) | CRHR1CRHR2 | |
| SCHEMBL1847680 | 0.85 | CRHR1 (1.00) | CRHR1CRHR2 | |
| SCHEMBL1987169 | 0.85 | CRHR1 (1.00) | CRHR1CRHR2 | |
| SCHEMBL13493840 | 0.85 | CRHR1 (1.00) | CRHR1CRHR2 | |
| SCHEMBL1847554 | 0.85 | CRHR1 (1.00) | CRHR1CRHR2 | |
| SCHEMBL1847556 | 0.85 | CRHR1 (1.00) | CRHR1CRHR2 | |
| SCHEMBL1852397 | 0.84 | CRHR1 (0.89) | CRHR1CRHR2 | |
| SCHEMBL1852399 | 0.84 | CRHR1 (0.89) | CRHR1CRHR2 | |
| SCHEMBL1850606 | 0.80 | CRHR1 (0.77) | CRHR1CRHR2 | |
| SCHEMBL1850605 | 0.80 | CRHR1 (0.77) | CRHR1CRHR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2531490-B1 | CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2014-10-15 | — | — | EP | claimed |
| US-20120316185-A1 | Cyclohexyl Amide Derivatives as CRF Receptor Antagonists | NOVARTIS AG (CH) | 2012-12-13 | — | — | US | claimed |
| US-20210379158-A1 | METHOD FOR PREVENTING OR TREATING HEART FAILURE BY ADMINISTERING A MEDICAMENT CONTAINING AN ANTAGONIST OF CORTICOTROPIN RELEASING HORMONE RECEPTOR 2 (CRHR2) | RAQUALIA PHARMA INC (JP) | 2021-12-09 | — | — | US | disclosed |
| US-11135270-B2 | Method for preventing or treating heart failure by administering a medicament containing an antagonist of corticotropin releasing hormone receptor 2 (CRHR2) | RAQUALIA PHARMA INC. (JP) | 2021-10-05 | — | — | US | disclosed |
| US-20190160151-A1 | MEDICAMENT FOR PREVENTING OR TREATING HEART FAILURE | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2019-05-30 | — | — | US | disclosed |
| EP-2531490-B1 | CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2014-10-15 | — | — | EP | disclosed |
| US-8835444-B2 | Cyclohexyl amide derivatives as CRF receptor antagonists | NOVARTIS AG (CH) | 2014-09-16 | — | — | US | disclosed |
| US-20120316185-A1 | Cyclohexyl Amide Derivatives as CRF Receptor Antagonists | NOVARTIS AG (CH) | 2012-12-13 | — | — | US | disclosed |
| EP-2531490-A1 | CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS | Novartis AG (CH) | 2012-12-12 | — | — | EP | disclosed |
| WO-2011095450-A1 | CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2011-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120316185-A1 | Cyclohexyl Amide Derivatives as CRF Receptor Antagonists | CRHR2, CRHR1, CRH | CRHR1 2/4885CRHR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.